Pharsight

Revlimid patents expiration

REVLIMID's oppositions filed in EPO
REVLIMID Litigations
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7855217 CELGENE Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Nov, 2024

(1 year, 1 month from now)

US7465800 CELGENE Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Apr, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7189740 CELGENE Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
Apr, 2023

(5 months ago)

US8404717 CELGENE Methods of treating myelodysplastic syndromes using lenalidomide
Apr, 2023

(5 months ago)

US9056120 CELGENE Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
Apr, 2023

(5 months ago)

US9155730 CELGENE Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
May, 2023

(4 months ago)

US8648095 CELGENE Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor
May, 2023

(4 months ago)

US9101621 CELGENE Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
May, 2023

(4 months ago)

US8530498 CELGENE Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
May, 2023

(4 months ago)

US9393238 CELGENE Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
May, 2023

(4 months ago)

US9101622 CELGENE Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone
May, 2023

(4 months ago)

US7968569 CELGENE Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
Oct, 2023

(6 days from now)

US7468363 CELGENE Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
Oct, 2023

(6 days from now)

US8492406 CELGENE Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
Oct, 2023

(6 days from now)

US8741929 CELGENE Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
Mar, 2028

(4 years from now)

Revlimid is owned by Celgene.

Revlimid contains Lenalidomide.

Revlimid has a total of 15 drug patents out of which 9 drug patents have expired.

Expired drug patents of Revlimid are:

  • US7189740
  • US8404717
  • US9056120
  • US9155730
  • US8648095
  • US9101621
  • US8530498
  • US9393238
  • US9101622

Revlimid was authorised for market use on 27 December, 2005.

Revlimid is available in capsule;oral dosage forms.

Revlimid can be used as use of revlimid (lenalidomide) for the treatment of previously treated marginal zone lymphoma in combination with a rituximab product; use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib; use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product, use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities, use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, wherein those patients have not received previous treatment for multiple myeloma, use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib, use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product, use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-hsct), use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone.

The generics of Revlimid are possible to be released after 08 March, 2028.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 28, 2026

Drugs and Companies using LENALIDOMIDE ingredient

Market Authorisation Date: 27 December, 2005

Treatment: Use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or...

Dosage: CAPSULE;ORAL

How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage

REVLIMID family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic